Select Page

With the start of its second clinical trial, NexImmune expands development of its unique non-genetically engineered T cell immunotherapies across a range of hematologic malignancies

With the start of its second clinical trial, NexImmune expands development of its unique non-genetically engineered T cell immunotherapies across a range of hematologic malignancies